Literature DB >> 15882977

Proteasomal degradation of Kir6.2 channel protein and its inhibition by a Na+ channel blocker aprindine.

Hiroaki Tanaka1, Junichiro Miake, Tomomi Notsu, Kazuhiko Sonyama, Norihito Sasaki, Kazuhiko Iitsuka, Masaru Kato, Shin-ichi Taniguchi, Osamu Igawa, Akio Yoshida, Chiaki Shigemasa, Yoshiko Hoshikawa, Yasutaka Kurata, Akihiko Kuniyasu, Hitoshi Nakayama, Nobuo Inagaki, Eiji Nanba, Goshi Shiota, Takayuki Morisaki, Haruaki Ninomiya, Masafumi Kitakaze, Ichiro Hisatome.   

Abstract

ATP-sensitive K+ channels (K(ATP):SUR2A+Kir6.2) play a pivotal role in cardiac protection against ischemia and reperfusion injury. When expressed in COS cells, Kir6.2 was short-lived with a half-life time of 1.9 h. The half-life time of Kir6.2 was prolonged by proteasome inhibitors MG132, ALLN, proteasome inhibitor 1, and lactacystine, but not at all by a lysosomal inhibitor chloroquine. MG132 also increased the level of ubiquitinated Kir6.2 without affecting its localization in the endoplasmic reticulum and Golgi apparatus. In electrophysiological recordings, MG132 augmented nicorandil-activated K(ATP) currents in COS cells expressing SUR2A and Kir6.2 as well as the same currents in neonatal rat cardiomyocytes. Like MG132, a Na+ channel blocker aprindine prolonged the half-life time of Kir6.2 and augmented K(ATP). Finally, both aprindine and MG132 inhibited the 20S proteasome activity in vitro. These results suggest a novel activity of aprindine to enhance K(ATP) currents by inhibiting proteasomal degradation of Kir 6.2 channels, which may be beneficial in the setting of cardiac ischemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882977     DOI: 10.1016/j.bbrc.2005.04.011

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  CaV2.2 channel cell surface expression is regulated by the light chain 1 (LC1) of the microtubule-associated protein B (MAP1B) via UBE2L3-mediated ubiquitination and degradation.

Authors:  María A Gandini; Daniel R Henríquez; Lizbeth Grimaldo; Alejandro Sandoval; Christophe Altier; Gerald W Zamponi; Ricardo Felix; Christian González-Billault
Journal:  Pflugers Arch       Date:  2014-02-26       Impact factor: 3.657

3.  Role of ubiquitin-proteasome degradation pathway in biogenesis efficiency of {beta}-cell ATP-sensitive potassium channels.

Authors:  Fei-Fei Yan; Chia-Wei Lin; Etienne A Cartier; Show-Ling Shyng
Journal:  Am J Physiol Cell Physiol       Date:  2005-06-29       Impact factor: 4.249

Review 4.  Subcellular trafficking and endocytic recycling of KATP channels.

Authors:  Hua-Qian Yang; Fabio A Echeverry; Assmaa ElSheikh; Ivan Gando; Sophia Anez Arredondo; Natalie Samper; Timothy Cardozo; Mario Delmar; Show-Ling Shyng; William A Coetzee
Journal:  Am J Physiol Cell Physiol       Date:  2022-05-04       Impact factor: 5.282

5.  Phosphorylation of eIF2alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase.

Authors:  Azmi Yerlikaya; Scot R Kimball; Bruce A Stanley
Journal:  Biochem J       Date:  2008-06-15       Impact factor: 3.857

6.  Inhibitory effects of local anesthetics on the proteasome and their biological actions.

Authors:  Udin Bahrudin; Masaki Unno; Kazuya Nishio; Akiko Kita; Peili Li; Masaru Kato; Masashi Inoue; Shunichi Tsujitani; Takuto Murakami; Rina Sugiyama; Yasushi Saeki; Yuji Obara; Keiji Tanaka; Hiroshi Yamaguchi; Isao Sakane; Yasushi Kawata; Toshiyuki Itoh; Haruaki Ninomiya; Ichiro Hisatome; Yukio Morimoto
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

Review 7.  Endocytosis: A Turnover Mechanism Controlling Ion Channel Function.

Authors:  Irene Estadella; Oriol Pedrós-Gámez; Magalí Colomer-Molera; Manel Bosch; Alexander Sorkin; Antonio Felipe
Journal:  Cells       Date:  2020-08-04       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.